Biotherapy Services Limited (BTS) receive a follow-on investment of £1.5m continued support of ongoing clinical trials for its regenerative wound care treatment. The funds will be used to support the clinical development of their patented treatment for Diabetic Foot Ulcers (“DFUs”). Diabetes affects 3.7m people...
Delveinsight Report names Biotherapy Services as one of the innovators in market sector set to increase by 14.1% by 2030 Healthcare and market research consultant, Delveignsight, released an analysis of the global DFU (Diabetic Foot Ulcer) market, naming Biotherapy Services as one of the key...
BIOTHERAPY SERVICES AWARDED INNOVATION PASSPORT FOR GROUNDBREAKING TREATMENT FOR DIABETIC FOOT ULCERS. WINDSOR, April 8, 2021 – Biotherapy Services Ltd (BTS), a clinical stage pharmaceutical biotechnology company developing novel autologous therapies for complex and chronic wounds, has been awarded the innovative medicine designation – the Innovation...
16th February 2021 - Biotherapy Services Ltd re-open trial to recruitment at Loughborough Hospital. Amidst difficult times, BTS are pleased to announce the RAPID-1 DFU clinical trial is open to recruitment at the Loughborough site. Working throughout the past year BTS has established a working partnership...
Specialist Mobile Wound Healing Clinic Goes on the Road to Provide Revolutionary New Treatments In a unique collaboration between award-winning Harley Street Skin clinic and Biotherapy Services Ltd., a state of the art mobile wound clinic will be on the road from October 5th. The first of...
The Stem for Britain programme is one of the most exciting platforms for the development and discovery of young talent in the disciplines of science, technology, engineering and mathematics, and we salute each of you as participants, finalists, award winners and future ‘game changers’! The timing...
At Biotherapy Services we are hugely excited by the proposal of the Medicines and Medical Device Bill introduced on 13/02/2020. Without this support of the UK Government, we would be unable to develop innovative point of care manufactured medicines providing important new treatment options for the people of...
Innovative biopharmaceutical company Biotherapy Services Ltd secures £3.0 million investment from Foresight £3.0 million investment from Foresight VCT and Foresight 4 VCT. Biotherapy Services Limited has developed a pioneering treatment for complex wounds and the product is in clinical trials for the treatment of diabetic...
Biotherapy Services appoints John Chiplin as Chairman We are pleased to announce the key appointment to the BTS Board of Dr John Chiplin PhD as Chairman. John is Managing Director of Newstar Ventures Ltd. and also Chairman of Scancell Holdings plc (LSE:SCLP) and has extensive UK...
8thMarch 2019 Biotherapy Services Limited Exciting Update RAPID-1 Diabetic Foot Ulcer [RAPID-1DFU] Randomised Controlled Trial The Board and Executive Management Team are delighted to announce that the treatment of patients has commenced on the RAPID-1DFU trial. The RAPID Biodynamic Haematogel treatment is the first-in-class, medicinal product under development for the...